Complaint: A 67-year-old female patient was referred to our clinic with a complaint of sudden decrease in
vision in her left eye for 3 days. She had been followed up in another center for 2 years with a diagnosis of
polypoid choroidal vasculopathy (PCV). A total of 8 doses of intravitreal anti-VEGF injections were applied
to the left eye in another center, and the last one had been 1 month prior. She stated that her hypertension
had been irregular for the last week, and her sudden decrease in vision began after a severe headache.
Treatment: the patient received a subtenon injection of 1.0 ml of autologous citrated PRP solution + 0.5 ml
bevacizumab. MagnoVision was applied for 30 minutes immediately after the injection, as well as once a day
for 9 consecutive days. Bromelain tablets were started orally twice a day. By the 5th session, the vitreous
hemorrhage had completely cleared, and the subretinal hemorrhage was greatly reduced. By the 10th session,
the subretinal hemorrhage had completely cleared, and a disciform scar remained in the macular area. The VA
in the treated left eye was improved to 0.1 BCVA from “hand motion” despite a macular lesion.
Treatment was planned as a combination of citrate for coagulum dispersion, Platelet Rich Plasma (PRP)
containing epithelial growth factor to increase the phagocytosis rate of the pigment epithelium pump,
AntiVEGF/Bevacizumab to prevent new hemorrhages and electromagnetic iontophoresis (MagnoVision) for
vibration of Iron molecules in erythrocytes. With suspicion of active infection, PRP was prepared
allogeneically from a healthy patient relative belonging to the same blood group. Allogeneic PRP was
prepared by refrigerating a total of 8 ml of blood taken from the patient relative into a sterile citrated PRP
tube. After centrifuging at +4 degrees Celsius, 2500 rpm, and 8 minutes, the lower 1/3 of the plasma formed
in the tube was withdrawn into a 2.5 ml injector, totaling 1 ml of PRP. 0.5 ml of Bevacizumab was added to
the syringe containing 1 ml of citrated PRP. A total of 1.5 ml of citrate, PRP and AntiVEGF mixture was
injected into the right subtenon space under topical anesthesia. Immediately after the subtenon injection,
the patient was fitted with a MagnoVision™ electromagnetic iontophoresis helmet. MagnoVision™ is a
stimulator and iontophoresis device specifically designed for retina/optic nerve diseases, which contains 9
coils and generates a 2000 mG magnetic field with a 42 Hertz vibration frequency that synchronously
stimulates the bulbus, visual pathways and occipital cortex. These parameters are fixed values by the
manufacturer that cannot be changed for patient safety. Each session is applied effectively and safely for
30 minutes. Electromagnetic iontophoresis and stimulation were applied once a day for 30 minutes for 10
consecutive days. A total of 3 subtenon injection and 10 sessions of Magnovison were applied.
Subretinal Hemorrhages, without surgery:
MAGNOVISION™ and Subtenon Bevacizumab + Platelet Rich Plasma Injection.
MAGNOVISION™ and Subtenon Bevacizumab + Platelet Rich Plasma Injection.
Preretinal SubILM Hemorrhage Treatment
Complaint: A 48-year-old female patient was referred to our clinic with complaints of sudden vision loss in
her right eye following cough attacks the day before. The patient was followed up in the Pulmonology clinic
with the diagnosis of pneumococcal pneumonia.
Treatment: Treatment was planned as a combination of citrate for coagulum dispersion, Platelet Rich
Plasma (PRP) containing epithelial growth factor to increase the phagocytosis rate of the pigment
epithelium pump, AntiVEGF/Bevacizumab to prevent new hemorrhages and electromagnetic iontophoresis
(Magnovision) for vibration of Iron molecules in erythrocytes. With suspicion of active infection, PRP was
prepared allogeneically from a healthy patient relative belonging to the same blood group. Allogeneic PRP
was prepared by refrigerating a total of 8 ml of blood taken from the patient relative into a sterile citrated
PRP tube. After centrifuging at +4 degrees Celsius, 2500 rpm, and 8 minutes, the lower 1/3 of the plasma
formed in the tube was withdrawn into a 2.5 ml injector, totaling 1 ml of PRP. 0.5 ml of Bevacizumab was
added to the syringe containing 1 ml of citrated PRP. A total of 1.5 ml of citrate, PRP and AntiVEGF mixture
was injected into the right subtenon space under topical anesthesia. Immediately after the subtenon
injection, the patient was fitted with a MagnoVision™ electromagnetic iontophoresis helmet. MagnoVision™
is a stimulator and iontophoresis device specifically designed for retina/optic nerve diseases, which
contains 9 coils and generates a 2000 mG magnetic field with a 42 Hertz vibration frequency that
synchronously stimulates the bulbus, visual pathways and occipital cortex. These parameters are fixed
values by the manufacturer that cannot be changed for patient safety. Each session is applied effectively
and safely for 30 minutes. Electromagnetic iontophoresis and stimulation were applied once a day for 30
minutes for 10 consecutive days. A total of 1 subtenon injection and 10 sessions of Magnovison were
applied. One day after subtenon injection and Magnovision, we observed that the subILM hemorrhage had
completely drained into the vitreous. After the 10th session of Magnovison, we observed that the vitreous
hemorrhage was cleared in front of the macula. After 10 sessions, VA was improved to 0.7 BCVA from “hand
motion”.
MAGNOVISION™ and Subtenon Bevacizumab + Platelet Rich Plasma Injection.
Submacular Hemorrhage Treatment
Complaint: A 19-year-old female patient presented with sudden vision loss following blunt trauma to her
right eye.
Treatment: the patient received a subtenon injection of 1.0 ml of autologous citrated PRP solution + 0.5 ml
bevacizumab. MagnoVision was applied for 30 minutes immediately after the injection, as well as once a day
for 9 consecutive days. A total of 3 subtenon injection (1st, 5th and 10th days) and 10 sessions of
Magnovison were applied. Bromelain tablets were started orally twice a day. By the 5th session, the
subretinal hemorrhage was greatly reduced. By the 10th session, the subretinal hemorrhage had completely
cleared, The VA was improved to 10/10 BCVA from 0.1
Treatment was planned as a combination of citrate for coagulum dispersion, Platelet Rich Plasma (PRP)
containing epithelial growth factor to increase the phagocytosis rate of the pigment epithelium pump,
AntiVEGF/Bevacizumab to prevent new hemorrhages and electromagnetic iontophoresis (Magnovision) for
vibration of Iron molecules in erythrocytes. Autologous PRP was prepared by refrigerating a total of 8 ml of
blood taken from the patient into a sterile citrated PRP tube. After centrifuging at +4 degrees Celsius, 2500
rpm, and 8 minutes, the lower 1/3 of the plasma formed in the tube was withdrawn into a 2.5 ml injector,
totaling 1 ml of PRP. 0.5 ml of Bevacizumab was added to the syringe containing 1 ml of citrated PRP. A total
of 1.5 ml of citrate, PRP and AntiVEGF mixture was injected into the right subtenon space under topical
anesthesia. Immediately after the subtenon injection, the patient was fitted with a MagnoVision
electromagnetic iontophoresis helmet. MagnoVision is a stimulator and iontophoresis device specifically
designed for retina/optic nerve diseases, which contains 9 coils and generates a 2000 mG magnetic field
with a 42 Hertz vibration frequency that synchronously stimulates the bulbus, visual pathways and occipital
cortex. These parameters are fixed values by the manufacturer that cannot be changed for patient safety.
Each session is applied effectively and safely for 30 minutes. Electromagnetic iontophoresis and
stimulation were applied once a day for 30 minutes for 10 consecutive days. A total of 3 subtenon injection
and 10 sessions of MagnoVison were applied.
MagnoVision™ indications: VITREOUS AND RETINAL HEMORRHAGES
Full text link: https://lnkd.in/d9MAmvjb
Tıbbi firmamız, halihazırda tedavisi bulunmayan bazı retina ve optik sinir
hastalıklarına çözüm sunmak amacıyla oftalmolojik tedavi cihazlarının
üretimi üzerinde çalışmaktadır.
Contact
info@bioretina.com.tr
+90 (312) 235 85 10
+90 (530) 321 75 90
Erler Mah. Dumlupınar Bulvarı Üstün
Dekocity İş Merkezi No:348/68
Etimesgut/ANKARA/TÜRKİYE
